S. 863 · 119th Congress · Commerce
Genomic Data Protection Act
- IntroducedMar 5, 2025 Done
- CommitteeReferred to Commerce, Science, and Transportation Current stage
- Senate floorNot yet Not reached yet
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
The Congressional Research Service hasn’t published a summary of this bill. Read the full text on Congress.gov.Who lobbies on it
1 organization · 1 filing · Q1 2025–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Pharmaceutical Research & Manufacturers of America Inc
1 of 7 quarters
“Issues related to biopharmaceutical innovation and intellectual property (no bill); issues related to intellectual property and Bayh-Dole in the Genomic Data Protection Act (S. 863 / no House bill); induced infringement.”
$37.9M lobbying spend in 2025, all issuesQ3 2025 filing
Organizations that named S. 863 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- Mar 5, 2025Read twice and referred to the Committee on Commerce, Science, and Transportation.
- Mar 5, 2025Introduced in Senate